Cargando…

Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique

An increase in the global aging population is leading to an increase in age-related conditions such as dementia and movement disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). The accurate prediction of risk factors associated with these dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahata, Ichiro, Sekimori, Tomoki, Oizumi, Hideki, Takeda, Atsushi, Fukunaga, Kohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487513/
https://www.ncbi.nlm.nih.gov/pubmed/37686075
http://dx.doi.org/10.3390/ijms241713267
_version_ 1785103261464788992
author Kawahata, Ichiro
Sekimori, Tomoki
Oizumi, Hideki
Takeda, Atsushi
Fukunaga, Kohji
author_facet Kawahata, Ichiro
Sekimori, Tomoki
Oizumi, Hideki
Takeda, Atsushi
Fukunaga, Kohji
author_sort Kawahata, Ichiro
collection PubMed
description An increase in the global aging population is leading to an increase in age-related conditions such as dementia and movement disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). The accurate prediction of risk factors associated with these disorders is crucial for early diagnosis and prevention. Biomarkers play a significant role in diagnosing and monitoring diseases. In neurodegenerative disorders like α-synucleinopathies, specific biomarkers can indicate the presence and progression of disease. We previously demonstrated the pathogenic impact of fatty acid-binding proteins (FABPs) in α-synucleinopathies. Therefore, this study investigated FABPs as potential biomarkers for Lewy body diseases. Plasma FABP levels were measured in patients with AD, PD, DLB, and mild cognitive impairment (MCI) and healthy controls. Plasma FABP3 was increased in all groups, while the levels of FABP5 and FABP7 tended to decrease in the AD group. Additionally, FABP2 levels were elevated in PD. A correlation analysis showed that higher FABP3 levels were associated with decreased cognitive function. The plasma concentrations of Tau, GFAP, NF-L, and UCHL1 correlated with cognitive decline. A scoring method was applied to discriminate between diseases, demonstrating high accuracy in distinguishing MCI vs. CN, AD vs. DLB, PD vs. DLB, and AD vs. PD. The study suggests that FABPs could serve as potential biomarkers for Lewy body diseases and aid in early disease detection and differentiation.
format Online
Article
Text
id pubmed-10487513
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104875132023-09-09 Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique Kawahata, Ichiro Sekimori, Tomoki Oizumi, Hideki Takeda, Atsushi Fukunaga, Kohji Int J Mol Sci Article An increase in the global aging population is leading to an increase in age-related conditions such as dementia and movement disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). The accurate prediction of risk factors associated with these disorders is crucial for early diagnosis and prevention. Biomarkers play a significant role in diagnosing and monitoring diseases. In neurodegenerative disorders like α-synucleinopathies, specific biomarkers can indicate the presence and progression of disease. We previously demonstrated the pathogenic impact of fatty acid-binding proteins (FABPs) in α-synucleinopathies. Therefore, this study investigated FABPs as potential biomarkers for Lewy body diseases. Plasma FABP levels were measured in patients with AD, PD, DLB, and mild cognitive impairment (MCI) and healthy controls. Plasma FABP3 was increased in all groups, while the levels of FABP5 and FABP7 tended to decrease in the AD group. Additionally, FABP2 levels were elevated in PD. A correlation analysis showed that higher FABP3 levels were associated with decreased cognitive function. The plasma concentrations of Tau, GFAP, NF-L, and UCHL1 correlated with cognitive decline. A scoring method was applied to discriminate between diseases, demonstrating high accuracy in distinguishing MCI vs. CN, AD vs. DLB, PD vs. DLB, and AD vs. PD. The study suggests that FABPs could serve as potential biomarkers for Lewy body diseases and aid in early disease detection and differentiation. MDPI 2023-08-26 /pmc/articles/PMC10487513/ /pubmed/37686075 http://dx.doi.org/10.3390/ijms241713267 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kawahata, Ichiro
Sekimori, Tomoki
Oizumi, Hideki
Takeda, Atsushi
Fukunaga, Kohji
Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title_full Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title_fullStr Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title_full_unstemmed Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title_short Using Fatty Acid-Binding Proteins as Potential Biomarkers to Discriminate between Parkinson’s Disease and Dementia with Lewy Bodies: Exploration of a Novel Technique
title_sort using fatty acid-binding proteins as potential biomarkers to discriminate between parkinson’s disease and dementia with lewy bodies: exploration of a novel technique
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487513/
https://www.ncbi.nlm.nih.gov/pubmed/37686075
http://dx.doi.org/10.3390/ijms241713267
work_keys_str_mv AT kawahataichiro usingfattyacidbindingproteinsaspotentialbiomarkerstodiscriminatebetweenparkinsonsdiseaseanddementiawithlewybodiesexplorationofanoveltechnique
AT sekimoritomoki usingfattyacidbindingproteinsaspotentialbiomarkerstodiscriminatebetweenparkinsonsdiseaseanddementiawithlewybodiesexplorationofanoveltechnique
AT oizumihideki usingfattyacidbindingproteinsaspotentialbiomarkerstodiscriminatebetweenparkinsonsdiseaseanddementiawithlewybodiesexplorationofanoveltechnique
AT takedaatsushi usingfattyacidbindingproteinsaspotentialbiomarkerstodiscriminatebetweenparkinsonsdiseaseanddementiawithlewybodiesexplorationofanoveltechnique
AT fukunagakohji usingfattyacidbindingproteinsaspotentialbiomarkerstodiscriminatebetweenparkinsonsdiseaseanddementiawithlewybodiesexplorationofanoveltechnique